the American Academy of Pediatrics Committee on Nutrition recommend selective screening of individuals between ages 2 and 20 years [2] . Currently, only those childrenwhose parents or grandparents developed premature atherosclerotic vascular disease (55 years or younger) or children who have one parent whose total cholesterol is 2400 mg/L are recommended for screening [21.8 The major atherogenic fraction of serum cholesterol is low-density lipoprotein cholesterol (LDL-C) [3, 4] . The NCEP has classified LDL-C concentrationsin children and adolescents from families with hypercholesterolemia or premature atherosclerosis into three main categories [2] , based on the 75th (1100 mgfL) and 90th percentile (1300 mgfL) of LDL-C in American children and adolescents: acceptable <1100 mgfL, borderline1100-1290 mg/L, and high 1300 mgfL. Plasma LDL-C is currently estimated in most clinical laboratories by the formula of Friedewald et al. [5, 6] , which is based on the observationthat,in the fasting state, very-low-density lipoprotein (VLDL) cholesterol is -20% of the total triglycerides(TG), measured in units of mg/L. Therefore, LDL-C = total cholesterol minus high-density lipoprotein cholesterol (HDL-C) minus (TG/5). This formula, however, has certain constraints [6] [7] [8] : It is invalidat TG concentrations 4000 mg/L and it can be utilized only in the fasting state [6] . Furthermore, the latestNCEP recommendations [9] define specific performance criteria for LDL-C assaysthatcannot be met by the Friedewald calculation [6] [7] [8] .
A new "direct"immunological procedure for detennining LDL-C (directLDL cholesterolor DLDL-C), LDL Cholesterol#{174}, has been developed by Genzyme Corp., Cambridge, MA, and ismarketed by Sigma Diagnostics, St.Louis,MO. The assay, which has been assessed in adults [10] [11] [12] , relies on the immunoseparation of LDL particles from HDL and VLDL by Nonstandard abbreviations: NCEP, National Cholesterol Education Program; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; ape, apolipoprotein; and DLDL-C, direct LDL-C. 8 To convert cholesterol mg/L to mmol/L, divide by 387.
9To convert triglyceride mgIL to mmoVL, divide by 883.
Historically, the 13-quantification assay included a heparin and manganese precipitation step, which has largely been replaced by precipitation with dextran sulfate and magnesium; hence, we describe the 13-quantification assay used as a "modified" procedure. [6, 13, 14] for determining LDL-C.
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Mate,ialsand Methods
PLASMA SAMPLES Of the 138 blood samples used in this study, 107 were from patientsattendingthe Children'sHospital Lipid Clinicbecause of a positivefamily history of premature atherosclerosis or hypercholesterolemia; 96 of these blood samples were obtained afteran overnight fastand the remaining 11 were drawn from nonfasting subjects. This study protocol was approved by the Internal Review Board of Children's Hospital, Boston. In addition to these Lipid Clinic samples, 31 plasma samples were obtained randomly (without conscious bias)from nonfasting hypertriglyceridemic hospital patients (TG 2500 mg/L). We therefore studieda total of 42 nonfasting patients. In allcaseswe assayed heparinized plasma that had been stored at 4 #{176}C [15] .
PROCEDURES
Modified (3-quantification [16] . We centrifuged230-jiL plasma samples at 250 000g for 3 h at 4 #{176}C in a Beckman TLIOO rotor with 7 X 20 mm polyallomertubes (Beckman Instruments, Palo Alto, CA). We then sliced the tubes and theircontentsso as to isolate the >1.006 kg/L infranate. Having restored the volume of the infranateto thatof the original sample by adding isotonic saline (9 g/L NaCI), we quantified its HDL-C content after precipitating [17] the LDL particles with MgCI2 and dextran sulfate (Mr 50 000).The LDL-C was then calculated as infranatant totalcholesterol-HDL-C, the VLDL-C having been removed by the ultracentrifugation. of the run-to-run precision study [18, 19] . 
Results
Heparinized
plasma is preferred to serum in our laboratory because it can be processed immediately aftercollection. In preliminary experiments we determined that the choice of heparinized plasma or serum had no statistically significant effect(P 0.37) on the outcome of the modified 13-quantificationor the DLDL-C assay (Table 1) .We thereforeused plasma for the remaining experiments. with the DLDL-C reagent once a week for 3 weeks, the samples being kept at4 #{176}C between measurements.
We found no significant difference between the initial (3-quantification LDL-C concentration and the initial or subsequent DLDL-C measurements (P 0.47).
All 96 plasma samples from fastingpediatric patientsof the Lipid Clinic were analyzed with the DLDL-C assay; analyzed for total cholesterol, HDL-C, and TG concentrations to calculate the Friedewald LDL-C values; and analyzed for LDL-C concentrations with the modified 13-quantification procedure. Both the Friedewald LDL-C and the DLDL-C were compared with the concentration obtained with the Reference Method.
The data from this study, summarized in (Fig. IA and B) . The resulting DLDL-C systematicerror calculatedwas 13 mg/L (1.6%), 117 mg/L (6.3%), and 132 mg/L (6.6%) at LDL-C concentrations of 810, 1850, and 2000 mg/L, respectively (see Materialsand Methods). The imprecision,defined here as the run-to-run CV (n = 20), was 5.2%, 4.5%, and 4.0% for these three respectiveLDL-C concentrations. The percentage totalerror (random error plus systematicerror)for these same DLDL-C concentrationswas 11.8%, 15.1%, and 14.4%, respectively, with a mean total error of 13.8%.
The effect of TG concentration on the performance of the DLDL-C assay for 42 nonfasting samples (mean ± SD TG, Results are given as mean ± SD, except where noted. 
1.
Triglycerides (mgIL) 4854 ± 5457 mg/L) was examined by comparing the results of relation to the LDL-C concentration determined by 13-quantification.
In the 96 fasting samples ( Fig. 2A) , this bias is negatively correlated with the 13-quantification LDL-C (r = -0.254, P <0.05); in the combined fastingand nonfasting patients(n = 138), however, the correlation is not significant (Fig. 2B) . Figure  3 displaysthe bias as a function of plasma TG concentration in both the 96 fasting (Fig. 3A) and the 138 combined fastingand nonfastingpatients (Fig. 3B) The blocks with the bold borders display the number of patients correctly classified by these assays (both absolute values and percentages). The remaining blocks are discrepant classifications.
The data in A and B are from the fasting patients (n = 96); those in C are from the combined fasting and nonfasting group (n = 138).
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Harris et al.: Direct LDL-cholesterol pediatric assay yses showed a significant positive correlation (P <0.01) between the bias and the plasma TG concentration.
We then assessedthe diagnosticperformance of the assays, using the NCEP cutpoints that divide the pediatric population on the basis of LDL-C concentrations into acceptable, borderline, and high categories. the DLDL-C correctly classified 80% (110 of 138) of the population.
We calculated the positive predictive value of each LDL-C method at both of the NCEP cutpoints for pediatric patients. For the DLDL-C assay, the positive predictive value at the 1300 mg/L and the >1100 mg/L concentrations was 85% and 95%, respectively. For the Friedewald formula, these were 97% and 98% at the same cutpoints. Both LDL-C testmethods yieldedcomparable results.
Discussion
In the routine clinical chemistry laboratory, the Friedewald
is widely used to calculate LDL-C but often fails to meet the most recentNCEP performance goals [9] . The current LDL-C referenceprocedure, known as 13-quantification [13] , kg/L). For any new LDL-C technique to be clinically useful and widely accepted, it should correlate with the 13-quantification method, which is the basisfor the database derived from the Lipid Research Clinics. However, given that 13-quantification actuallymeasures a heterogeneous population of particles, the potential task of developing a precise and accuratedirectassayfordetermining the cholesterol component of this "wide-density" LDL fraction appears all the more difficult [13, [20] [21] [22] . Here, we describe the performance of a newly introduced LDL-C assay (DLDL-C) and its ability to classify hyperlipidemic children correctly according to the NCEP cutpoints.
The DLDL-C assay requires a single measurement, whereas measurements of total cholesterol, HDL-C, and TG are needed for the Friedewald calculation.
The DLDL-C assay is unaf- 10/11 (91) Results are given as no. of subjects correctly classified/total no. of subjects (and % correctlyclassified).
find that DLDL-C-assayed results are stableat4 #{176}C forat least 3 weeks.
The random error of an assay is established by performing replicate measurements of a sample. The run-to-run imprecision of the DLDL-C assay has a concentration-dependent CV range of 4-5.2%, and therefore does not always meet the CV recommended by the NCEP ( 4%). Initially, the estimation of the run-to-run precision of the DLDL-C assay presented a problem.
Our experience with the manufacturer's lyophilized controls has been that, once reconstituted and stored at 4 #{176}C, they show a gradual upward drift of measured LDL-C concentrations over a 2-3 week period, resulting in an increase of -6-10%.
When the reconstituted control material was aliquoted and stored at 4#{176}C in 1.5-mL Microfuge tubes, the variation was less. Freezing the control material does not appear to be a viable alternative because frozen samples show a continuous time-dependent decrease in DLDL-C concentration [10] . Table 2 and Fig. 1 demonstrate that in the fasting pediatric subjects the DLDL-C assay had a negative mean bias (±SD) of -98 (±2 15) mg/L vs the reference procedure.
In the same population the bias of the Friedewald calculation was + 59 (± 172) mgfL. Another indicator of analytical error, the systematic error of an assay, may be further quantified by least-squares linear regression [18, 19] . The NCEP performance goals require that an LDL-C assay have an analytical bias of ± 4.0% [9] . We note, however, that substituting a range of values (600-3500 mgfL) into our DLDL-C regression equation for fasting patients (y = 0.9x + 68) yielded calculated systematic errors of + 1.4% to -8.0%
(data not shown). We therefore found a greater negative bias than did several other investigators who studied the performance of the DLDL-C assay in adults [10] [11] [12] . The explanation for the overall negative bias of the DLDL-C is unclear. Theoretically, the DLDL-C assay determines the cholesterol that is present only in LDL and lipoprotein(a) particles-and therefore not in intermediate-density lipoprotein [13] , unlike the 13-quantification procedure. Perhaps this is the source of the DLDL-C negative bias. Alternatively, some LDL-containing plasma may be trapped by the latex beads in the DLDL-C assay and thereby be excluded from the filtrate [10] . Combining systematic error and random error to obtain the total analytical error [18, 19] , we obtained a mean total analytical error in the 96 fasting patients at three DLDL-C concentrations of 13.8% (the NCEP recommends a total analytical error of l2%).
In contrast, for nonfasting samples (Table 2) , the DLDL-C assay had a mean positive bias of +177 (±432) mg/L. Further analysis showed a positive correlation between plasma TG concentration and DLDL-C bias (DLDL-C -(3-quantification LDL-C) in both the fasting patients and the combined fasting and nonfasting patients (Fig. 3) . Two possible explanations for the DLDL-C positive bias are that (a) the anti-apo A-I and anti-apo E on the latex beads become saturated in hypertriglyceridemic plasma, thus allowing the excess TG-rich lipoproteins to escape into the filtrate and increase the measured cholesterol, or (b) the larger TG-rich particles present in hypertriglyceridemia interfere with antibody binding through steric hindrance [10] . Awareness of the triglyceride-dependent bias of the DLDL-C assay is important in pediatrics because mean TG concentrations in this population are low relative to adults [1] , implying that this negative bias will predominate. We also noted an inverse correlation between the DLDL-C bias and the LDL-C measured by 13-quantification (Fig. 2) , the negative bias becoming more pronounced at higher LDL-C concentrations. Despite the above-mentioned negative systematic error of the DLDL-C assay in fasting pediatric patients, the diagnostic performance of this assay was at least comparable with that of the Friedewald calculation as assessed by its ability to correctly classify such patients into the three NCEP groups. However, the positive predictive value of the Friedewald calculation was better than that of the DLDL-C assay at the 1300 mg/L concentration.
When nonfasting patients were included in the analysis, the diagnostic performance of the DLDL-C assay was largelyunaffected (Fig.4C) . TG concentrations >4000 mg/L (for which use of the Friedewald calculation is precluded) are unusual in pediatric practice. In a fasting pediatric population, one would therefore commonly be able to use either the Friedewald calculation or the DLDL-C assay. Our results indicate that the latter would give little gain in terms of analytical or diagnostic performance. We do, however, envision an application for the DLDL-C assay in nonfasting pediatric patients, the diagnostic performance of this assay being comparable in both the fasting and nonfasting groups. The DLDL-C assay need not be used in the initial assessment of new pediatric hyperlipidemic patients. Because fasting values for TG and HDL-C are needed in such patients, LDL-C can be adequately derived from the Friedewald calculation.
In conclusion, therefore, despite its borderline-acceptable analytical performance with respect to the NCEP performance goals for total error, we recognize that the DLDL-C assay is a potentially useful tool in the follow-up nonfasting management of children with hypercholesterolemia.
This population is particularly relevant for use with such a method because patient compliance for drawing a morning fasting blood sample is often achieved with some difficulty.
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